Skip to content

Clinical trials

Phase 1 Attention Deficit Disorder with Hyperactivity trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Attention Deficit Disorder with Hyperactivity Phase: Phase 1 Country / region: United States Clear all

47 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20021
20052
20092
20101
20113
20121
20132
20143
20152
20162
20174
20184
20192
20204
20213
20234
20243
20251
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed39
Terminated3
Enrolling by invitation2
Recruiting1
Unknown status1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Otsuka Pharmaceutical Development & Commercialization, Inc.7
PhenoSolve, LLC3
Shire3
Yale University3
Aevi Genomic Medicine, LLC, a Cerecor company2
Massachusetts General Hospital2
The National Center on Addiction and Substance Abuse at Columbia University2
University of California, Los Angeles2
Avekshan LLC1
Boston Children's Hospital1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Attention Deficit Disorder with Hyperactivity47
Conduct Disorder2
Oppositional Defiant Disorder2
Alcoholism1
Anemia, Sickle Cell1
Autism Spectrum Disorder1
Autistic Disorder1
Binge-Eating Disorder1
Central Nervous System Diseases1
Cocaine-Related Disorders1

Trials

Showing 1 to 25 of 47. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.